Literature DB >> 9766262

The use of colour slides in the assessment of changes in soft-tissue involvement in Graves' ophthalmopathy.

M N Gerding1, M F Prummel, R Kalmann, L Koornneef, W M Wiersinga.   

Abstract

There is a need for more reliable and validated methods to assess the eye changes in Graves' disease. Such measurements are now available for the assessment of proptosis, eye muscle dysfunction, and optic nerve involvement. However, no validated objective measurement exists for NO SPECS class II signs. The present study compares the use of colour slides with clinical grading for assessing soft-tissue involvement. Forty-three patients were treated with retrobulbar irradiation. Pre-treatment, and 6 months post-treatment the severity of class II signs was graded from 0 to grade c in two ways; 1) Clinically, by two independent, experienced observers, who recorded their scores on the same day; 2) From colour slides, taken at the same visits, which were graded afterwards in one session independently by the same observers. Inter-observer agreement about clinical grading was low (Kappa 0.32), and was not improved by using the slides (Kappa 0.35). However, by using the clinical scores, the observers disagreed on treatment outcome in 21/43 patients (49%), whereas using the slides disagreement occurred in only 6/43 (14%, p < 0.01). It is concluded that the grading of soft-tissue involvement is highly subjective. However, the use of colour slides does provide a more reliable way to assess a treatment effect and should be used in clinical trials.

Entities:  

Mesh:

Year:  1998        PMID: 9766262     DOI: 10.1007/BF03347327

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  10 in total

1.  Classification of eye changes of Graves' disease.

Authors: 
Journal:  Thyroid       Date:  1992       Impact factor: 6.568

2.  Why the NOSPECS classification of Graves' eye disease should be abandoned, with suggestions for the characterization of this disease.

Authors:  B R Frueh
Journal:  Thyroid       Date:  1992       Impact factor: 6.568

3.  Clever is not enough: NOSPECS is form in search of function.

Authors:  C A Gorman
Journal:  Thyroid       Date:  1991       Impact factor: 6.568

4.  Classification of the eye changes of Graves' disease.

Authors:  W M Wiersinga; M F Prummel; M P Mourits; L Koornneef; H R Buller
Journal:  Thyroid       Date:  1991       Impact factor: 6.568

5.  Graves' ophthalmopathy: II. Correlation of clinical signs with measures derived from computed tomography.

Authors:  E S Hallin; S E Feldon
Journal:  Br J Ophthalmol       Date:  1988-09       Impact factor: 4.638

6.  Modification of the classification of the eye changes of Graves' disease: recommendations of the Ad Hoc Committee of the American Thyroid Association.

Authors:  S C Werner
Journal:  J Clin Endocrinol Metab       Date:  1977-01       Impact factor: 5.958

7.  Uniocular fields of fixation in thyroid eye disease.

Authors:  D H Steel; H B Hoh; M J Potts; R A Harrad
Journal:  Eye (Lond)       Date:  1995       Impact factor: 3.775

8.  Clinical classification of Graves' ophthalmopathy. Identification of risk factors for optic neuropathy.

Authors:  S E Feldon; S Muramatsu; J M Weiner
Journal:  Arch Ophthalmol       Date:  1984-10

9.  The reliability of Hertel exophthalmometry. Observer variation between physician and lay readers.

Authors:  D C Musch; B R Frueh; J R Landis
Journal:  Ophthalmology       Date:  1985-09       Impact factor: 12.079

10.  Measuring eye movements in Graves ophthalmopathy.

Authors:  M P Mourits; M F Prummel; W M Wiersinga; L Koornneef
Journal:  Ophthalmology       Date:  1994-08       Impact factor: 12.079

  10 in total
  2 in total

Review 1.  Does radiotherapy have a role in the management of thyroid orbitopathy? View 1.

Authors:  Kimberley P Cockerham; John S Kennerdell
Journal:  Br J Ophthalmol       Date:  2002-01       Impact factor: 4.638

2.  Both Th1- and Th2-derived cytokines in serum are elevated in Graves' ophthalmopathy.

Authors:  I M Wakelkamp; M N Gerding; J W Van Der Meer; M F Prummel; W M Wiersinga
Journal:  Clin Exp Immunol       Date:  2000-09       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.